期刊
CANCER DISCOVERY
卷 7, 期 3, 页码 248-249出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-17-0057
关键词
-
类别
资金
- National Institute for Health Research (NIHR) Royal Marsden (RM)/Institute of Cancer Research (ICR) Biomedical Research Centre (BRC)
FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in FGFR2 and intratumoral heterogeneity drive resistance in patients with FGFR2 - translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic. (C) 2017 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据